Study Reveals New Clues to Understand Brain Stimulation
Findings could help guide clinicians in selecting stimulation sites and improve treatment for various neurological and psychiatric disorders
EMBARGOED FOR RELEASE: Monday, September 29, 2014, 3 p.m. ETCONTACT: Bonnie Prescott, (617) 667-7306; email@example.com
STUDY REVEALS NEW CLUES TO HELP UNDERSTAND BRAIN STIMULATION Results could help guide clinicians in selecting stimulation sites to improve treatment for patients with various neurological and psychiatric disorders
Newswise — BOSTON – Over the past several decades, brain stimulation has become an increasingly important treatment option for a number of psychiatric and neurological conditions.
Divided into two broad approaches, invasive and noninvasive, brain stimulation works by targeting specific sites to adjust brain activity. The most widely known invasive technique, deep brain stimulation (DBS), requires brain surgery to insert an electrode and is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Parkinson’s disease and essential tremor. Noninvasive techniques, including transcranial magnetic stimulation (TMS), can be administered from outside the head and are currently approved for the treatment of depression. Brain stimulation can result in dramatic benefit to patients with these disorders, motivating researchers to test whether it can also help patients with other diseases.
But, in many cases, the ideal sites to administer stimulation have remained ambiguous. Exactly where in the brain is the best spot to stimulate to treat a given patient or a given disease?
Now a new study in the Proceedings of the National Academy of Sciences (PNAS) helps answer this question. Led by investigators at Beth Israel Deaconess Medical Center (BIDMC), the findings suggest that brain networks – the interconnected pathways that link brain circuits to one another-- can help guide site selection for brain stimulation therapies. “Although different types of brain stimulation are currently applied in different locations, we found that the targets used to treat the same disease are nodes in the same connected brain network,” says first author Michael D. Fox, MD, PhD, an investigator in the Berenson-Allen Center for Noninvasive Brain Stimulation and in the Parkinson’s Disease and Movement Disorders Center at BIDMC.
“This may have implications for how we administer brain stimulation to treat disease. If you want to treat Parkinson’s disease or tremor with brain stimulation, you can insert an electrode deep in the brain and get a great effect. However, getting this same benefit with noninvasive stimulation is difficult, as you can’t directly stimulate the same site deep in the brain from outside the head,” explains Fox, an Assistant Professor of Neurology at Harvard Medical School (HMS). “But, by looking at the brain’s own network connectivity, we can identify sites on the surface of the brain that connect with this deep site, and stimulate those sites noninvasively.”
Brain networks consist of interconnected pathways linking brain circuits or loops, similar to a college campus in which paved sidewalks connect a wide variety of buildings.
In this paper, Fox led a team that first conducted a large-scale literature search to identify all neurological and psychiatric diseases where improvement had been seen with both invasive and noninvasive brain stimulation. Their analysis revealed 14 conditions: addiction, Alzheimer’s disease, anorexia, depression, dystonia, epilepsy, essential tremor, gait dysfunction, Huntington’s disease, minimally conscious state, obsessive compulsive disorder, pain, Parkinson disease and Tourette syndrome. They next listed the stimulation sites, either deep in the brain or on the surface of the brain, thought to be effective for the treatment of each of the 14 diseases.
“We wanted to test the hypothesis that these various stimulation sites are actually different spots within the same brain network,” explains Fox. “To examine the connectivity from any one site to other brain regions, we used a data base of functional MRI images and a technique that enables you to see correlations in spontaneous brain activity.” From these correlations, the investigators were able to create a map of connections from deep brain stimulation sites to the surface of the brain. When they compared this map to sites on the brain surface that work for noninvasive brain stimulation, the two matched.
“These results suggest that brain networks might be used to help us better understand why brain stimulation works and to improve therapy by identifying the best place to stimulate the brain for each individual patient and given disease,” says senior author Alvaro Pascual-Leone, MD, PhD, the Director of the Berenson-Allen Center for Noninvasive Brain Stimulation at BIDMC and Professor of Neurology at HMS. “This study illustrates the potential of gaining fundamental insights into brain function while helping patients with debilitating diseases, and provides us with a powerful way of selecting targets based on their connectivity to other regions that can be widely applied to help guide brain stimulation therapy across multiple neurological and psychiatric disorders.”
“As we’re trying different types of brain stimulation for different diseases, the question comes up, ‘How does one relate to the other?’” notes Fox. “In other words, can we use the success in one to help design a trial or inform how we apply a new type of brain stimulation? Our new findings suggest that resting-state functional connectivity may be useful for translating therapy between treatment modalities, optimizing treatment and identifying new stimulation targets.”
In addition to Fox and Pascual-Leone, study coauthors include Randy L. Buckner and Hesheng Liu of the Athinoula A. Martinos Center for Biomedical Imaging, Harvard Medical School; Mallar M. Chakravarty of the Douglas Mental Health Institute and McGill Unversity, QC, Canada; and Andres M. Lozano of Toronto Western Hospital, University of Toronto, Canada.
This study was supported, in part, by National Institutes of Health grants K23NS083741, R01HD069776, R01NS073601, R21MH099196, R21NS082870, R21NS085491, and R21HD07616, as well as grants from the American Academy of Neurology/American Brain Foundation; Harvard Clinical and Translational Science Center/Harvard Catalyst; the Michael J. Fox Foundation; the Sidney R. Baer, Jr. Foundation; and the National Football League Players Association.
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and currently ranks third in National Institutes of Health funding among independent hospitals nationwide.
BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Health Care, Beth Israel Deaconess HealthCare, Community Care Alliance, and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Senior Life and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.